RegeneRx Issues Update on Phase 3 Dry Eye Trial

Rhea-AI Summary

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced an update on its Phase 3 dry eye clinical trial (ARISE-3) enrollment status. The company is developing Tβ4 therapeutic peptides for tissue protection and regeneration. Currently, RegeneRx has three drug candidates under clinical development for various medical indications, including ophthalmic and cardiac uses. The ophthalmic product RGN-259 is particularly noted for its Phase 3 trials aimed at treating dry eye syndrome and neurotrophic keratitis in the U.S.

Positive

• Successful enrollment progress in Phase 3 trial (ARISE-3) for dry eye syndrome.
• Development of three drug candidates targeting diverse medical conditions.
• Existing strategic licensing agreements in multiple international markets.

Negative

• None.

ROCKVILLE, Md., Aug. 19, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the status of patient enrollment in its phase 3 dry eye clinical trial (ARISE-3). http://www.regenerx.com/2020-08-19-August-19-2020-Update-on-ARISE-3-Dry-Eye-Trial

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac/TBI and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world.  RGN-259, the Company's ophthalmic eye drop, is currently in Phase 3 clinical trials for dry eye syndrome and neurotrophic keratitis in the U.S.

Forward Looking Statements

Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, but are not limited to, competitive products, statements from us or our joint venture regarding strategic and research partnerships, status of clinical trials, reclassification of our drug candidates from drugs to biologics, regulatory applications and approvals, the development and value of our drug candidates, and the use of our drug candidates to treat various conditions. All forward-looking statements are expectations and estimates based upon information obtained and calculated by the Company at this time and are subject to change. Moreover, there is no guarantee any clinical trial will be successful or confirm previous clinical results. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2019, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this shareholder letter represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

For RegeneRx:
Lori Herman
301.208.9191
las@regenerx.com  

 

View original content:http://www.prnewswire.com/news-releases/regenerx-issues-update-on-phase-3-dry-eye-trial-301114921.html

SOURCE RegeneRx Biopharmaceuticals, Inc.

FAQ

What is RegeneRx Biopharmaceuticals focusing on in its clinical trials?

RegeneRx is developing therapeutic peptides, primarily Tβ4, for tissue protection and regeneration, currently focusing on ophthalmic conditions.

What is the status of the ARISE-3 trial for RGRX?

The ARISE-3 trial is in Phase 3, with updates on patient enrollment posted by RegeneRx.

What implications does the Phase 3 trial have for RGRX?

Successful completion of the Phase 3 trial could significantly impact RGRX's market position and potential revenue generation.

When did RegeneRx provide an update on the ARISE-3 trial?

RegeneRx posted the update on August 19, 2020.